These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21561405)

  • 1. New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia.
    Laurenti L; De Padua L; D'Arena G; Vannata B; Innocenti I; Tarnani M; Deaglio S; Sica S; Efremov DG; Leone G
    Mini Rev Med Chem; 2011 Jun; 11(6):508-18. PubMed ID: 21561405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy.
    Stephens DM; Byrd JC
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):303-27. PubMed ID: 23561475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
    Robak T
    Expert Rev Hematol; 2014 Dec; 7(6):841-57. PubMed ID: 25249370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
    Robak T
    Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
    Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T
    BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab in B-cell chronic lymphocytic leukemia.
    Shapira I; Grossbard ML
    Clin Lymphoma; 2004 Mar; 4(4):228-9. PubMed ID: 15072614
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of alemtuzumab in chronic lymphocytic leukemia.
    Nabhan C
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):115-21. PubMed ID: 16231849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging treatments for chronic lymphocytic leukaemia.
    Robak T; Jamroziak K; Robak P
    Drugs; 2009; 69(17):2415-49. PubMed ID: 19911856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
    Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
    J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.
    Robak T
    Curr Cancer Drug Targets; 2008 Mar; 8(2):156-71. PubMed ID: 18336199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rediscovering alemtuzumab: current and emerging therapeutic roles.
    Gribben JG; Hallek M
    Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
    Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
    Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD37 antibodies for chronic lymphocytic leukemia.
    Robak T; Robak P
    Expert Opin Biol Ther; 2014 May; 14(5):651-61. PubMed ID: 24555705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia.
    Nabhan C; Rosen ST
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):75-80. PubMed ID: 11842392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
    Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
    Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
    Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.